



**FOR IMMEDIATE RELEASE
NEWS RELEASE**

TSX Venture: **AMF**

AMORFIX LIFE SCIENCES LTD. TO BEGIN TRADING

TORONTO, ON, October 3, 2005 – Amorfix Life Sciences Ltd. (TSX-V – AMF) is pleased to announce that the TSX Venture Exchange has granted final acceptance of its listing application and that trading will commence today under the symbol “AMF”.

Amorfix Life Sciences Ltd. is the continued corporation resulting from the amalgamation of its predecessor corporation of the same name and Luxor Developments Inc. The amalgamation was completed on September 21, 2005, on which date Amorfix became a reporting issuer under the securities laws of British Columbia and Alberta.

Amorfix is an emerging theranostics company focused on the diagnosis and treatment of neurodegenerative diseases, where aggregated misfolded proteins (AMPs) are prevalent. These include aggregated misfolded prion protein which makes up “prions,” the infectious agents of the Transmissible Spongiform Encephalopathies (TSE), such as Bovine Spongiform Encephalopathy (BSE or "mad cow disease") and the human form, variant Creutzfeldt-Jakob Disease (vCJD), as well as degenerative diseases such as Alzheimer’s Disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Parkinson’s Disease (PD). Amorfix’s predecessor was formed in January 2004 to commercialize the discoveries of the epitope protection (EP) technologies at the University of Toronto discovered by Drs. Neil Cashman and Marty Lehto. These discoveries position the company to become the world authority on AMP diseases. The company will use this new knowledge to develop diagnostic kits, therapeutics and prophylactics for AMP diseases.

For further information, please contact:

Dr. George Adams, President and CEO
Amorfix Life Sciences Ltd.
416-557-4647

James Parsons, CFO
Amorfix Life Sciences Ltd.
416-705-5686

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.